Søgeresultater - Ursula A. Matulonis

Refine Results
  1. 1
    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential af Tarra Evans, Ursula A. Matulonis

    Udgivet 2017
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  2. 2
    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? af Ursula A. Matulonis, Bradley J. Monk

    Udgivet 2017
    Få fuldtekst Få fuldtekst
    Carta
    Føj til favoritter
    Saved in:
  3. 3
    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies af Elizabeth K. Lee, Ursula A. Matulonis

    Udgivet 2020
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  4. 4
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations af Jennifer Veneris, Ursula A. Matulonis, Joyce F. Liu, Panagiotis A. Konstantinopoulos

    Udgivet 2019
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  5. 5
    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers

    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers af Elizabeth K. Lee, David L. Kolin, Ursula A. Matulonis, Britt Erickson

    Udgivet 2025
    Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  6. 6
    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials af Ursula A. Matulonis, Amit M. Oza, Tony W. Ho, Jonathan A. Ledermann

    Udgivet 2014
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  7. 7
    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies af Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Elizabeth M. Swisher

    Udgivet 2016
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  8. 8
    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer af S. Percy Ivy, Joyce F. Liu, Jung‐Min Lee, Ursula A. Matulonis, Elise C. Kohn

    Udgivet 2016
    Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  9. 9
    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines

    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines af Brian J. Druker, Keiko Okuda, Ursula A. Matulonis, Ravi Salgia, Thomas M. Roberts, JD Griffin

    Udgivet 1992
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  10. 10
    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor af Emily Robinson, Ursula A. Matulonis, Percy Ivy, Suzanne Berlin, Karin Tyburski, Richard T. Penson, Benjamin D. Humphreys

    Udgivet 2010
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  11. 11
    Ovarian cancer

    Ovarian cancer af Ursula A. Matulonis, Anil K. Sood, Lesley Fallowfield, Brooke E. Howitt, Jalid Sehouli, Beth Y. Karlan

    Udgivet 2016
    Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  12. 12
    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. af Ursula A. Matulonis, Chrysoula Dosiou, GJ Freeman, Christine Lamont, Peter Mauch, L M Nadler, James D. Griffin

    Udgivet 1996
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  13. 13
    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma

    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma af Elizabeth H. Stover, Colleen M. Feltmate, Ross S. Berkowitz, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

    Udgivet 2018
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  14. 14
    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health

    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health af Alexi A. Wright, Nancy L. Keating, Tracy A. Balboni, Ursula A. Matulonis, Susan D. Block, Holly G. Prigerson

    Udgivet 2010
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  15. 15
    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study

    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study af Melissa A. Merritt, Megan S. Rice, Mollie E. Barnard, Susan E. Hankinson, Ursula A. Matulonis, Elizabeth M. Poole, Shelley S. Tworoger

    Udgivet 2018
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  16. 16
    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks

    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks af Kun‐Hsing Yu, Vincent J. Hu, Feiran Wang, Ursula A. Matulonis, George L. Mutter, Jeffrey A. Golden, Isaac S. Kohane

    Udgivet 2020
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  17. 17
    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine af Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O’Malley, Ursula A. Matulonis, Gottfried E. Konecny

    Udgivet 2023
    Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  18. 18
    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer

    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer af Michelle Samora, José Eduardo Levi, Sergio Nicolau, Edvane De Domenico, Ursula A. Matulonis, Audrey Tieko Tsunoda, Pâmela Perez Leite, Rafael Schmerling

    Udgivet 2022
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  19. 19
    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance

    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance af Raphaël Ceccaldi, Kevin W. O’Connor, Kent W. Mouw, Adam Y. Li, Ursula A. Matulonis, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos

    Udgivet 2015
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  20. 20
    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells af Young Eun Choi, Chiara Battelli, Jacqueline Watson, Joyce F. Liu, Jennifer Curtis, Alexander Morse, Ursula A. Matulonis, Dipanjan Chowdhury, Panagiotis A. Konstantinopoulos

    Udgivet 2014
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:

Søgeredskaber: